Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Piracetam | Sabroxy (Oroxylum indicum) | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 1200-4800 mg/day divided into 2-3 doses | — |
| Timing | With or without food; split doses morning and afternoon to maintain plasma levels | — |
| Cycle Duration | Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment | — |
| Evidence Level | moderate_human | Emerging |
Positive allosteric modulator of AMPA receptors, binding at a unique site along the dimer interface to reduce desensitization and deactivation. Inhibits N-type calcium channels at clinically relevant CNS concentrations. Enhances membrane fluidity of neuronal phospholipids and modulates neurotransmission across cholinergic and glutamatergic systems.
1200-4800 mg/day divided into 2-3 doses
With or without food; split doses morning and afternoon to maintain plasma levels
Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment
Contains oroxylin A — a flavonoid that inhibits PDE (phosphodiesterase), increases BDNF, and modulates dopamine signaling. Enhances focus and motivation without stimulant side effects. Also acts as a mild MAO-B inhibitor, preserving dopamine levels.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →